Although some studies found that an increased monocyte count is a predictive, short-term marker of unfavorable outcomes for patients with acute heart failure (HF), others have reported that monocytosis predicts prolonged survival.
Introduction
Several biomarkers and tests have been established as useful for assessing the prognosis of patients with acute heart failure (HF) [1] and various types of inflammatory cells, including monocytes, lymphocytes, eosinophils, and neutrophils, have been involved in coronary heart disease. [2, 3] Experimental data showed that an increased monocyte count may be useful as a predictive biomarker, and as an indicator of unfavorable outcomes among patients with acute coronary syndromes, post-infarction, HF, coronary artery disease (CAD), and atherosclerosis. It is also associated with increased in-hospital mortality. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Monocytes play an important role in inflammatory, vasculogenetic processes, as well as in regeneration of the vascular wall and in the development of HF. [4, 5, [9] [10] [11] [12] [13] [14] [15] Characterization of 3 subgroups of monocytes and their related contribution to either aggravation or amelioration of HF needs further elucidation. In depth understanding of the mechanisms involved in these effects is needed as well. [4] Shahid et al [2] recently provided a comprehensive analysis of the role of monocytes in heart failure. They highlighted the stimulating but commonly antagonizing effects of monocytemediated myocardial inflammation, that is regeneration and remodeling, as opposed to dilatation and fibrosis.
Monocyte platelet aggregates (MPA) are increased in patients with HF and believed to be associated with monocytes from Mon1 and Mon2 subgroups (also called "classical monocytes"). [6] The Mon1 subgroup monocytes (Mon1, antigen processing and presentation CD14 ++ CD16 -CCR2 + ) are recognized as phagocytes and play a role in first-line fortification and defense processes.
Mon3 stimulate "patrolling" function and tissue repair. The Mon3 (Ly-6C -) subgroup of monocytes promotes myocardial healing through myofibroblast accumulation, angiogenesis, and collagen deposition. [1] Ly-6Cmonocytes, notwithstanding, have been found to have anti-inflammatory properties. This subset promotes myocardial healing after an infarction through the processes of myoblast activation, angiogenesis, and collagen formation. In the absence of inflammation, Ly6C + transforms into Ly6C -, which predominates in the circulation, binding to vascular endothelium using CX3CR1 receptors. In response to bacterial infection, Ly-6Ccells release anti-inflammatory cytokines (namely, IL-10). [1, 15] The response to inflammation triggers the differentiation of monocytes into M2 macrophages, which in turn, release anti-inflammatory cytokines central to tissue repair. [15] This study investigated whether monocytes have an adverse or defensive effect on outcomes among patients with long-term, chronic HF. Most previous studies did not differentiate between chronic and acute HF. In acute HF, monocytes Mon1 and Mon2 predominate and increase during exacerbations.
Methods

Study design
This historical cohort, long-term, follow-up study included all patients treated in the special HF Unit at the Tel Aviv Sourasky Medical Center from January 1, 2000 to June 30, 2001 who met the study inclusion criteria. These patients were followed until January 1, 2017 or until death, if sooner.
Exclusion criteria
Excluded were patients with conditions known to affect white blood cell count, especially monocyte count (malignant disease with diffuse metastases, chemo-and/or radiotherapy), medications known to affect blood count (steroids), acute renal failure, active hepatic disease, severe chronic obstructive pulmonary disease, or acute infectious disease. Patients with conditions that could cause acute HF (those who in less the previous 3 months had acute MI, percutaneous coronary intervention, heart surgery, or those hospitalized for any reason) were also excluded.
Baseline blood samples for complete blood counts (CBC), including automatic differential counts, renal function tests, and lipid profile were obtained at the first visit. Clinical and laboratory measurements were obtained at subsequent follow-up visits.
Systolic HF (reduced ejection fraction) was defined as a LVEF 40%, [1, 16] based on echocardiography or radionuclide ventriculography. LVEF >40% was defined as HF with preserved ejection fraction (diastolic dysfunction).
During their first visit to the HF Unit, all participants were examined and medical history was obtained, including current medications. Patients underwent physical examination that included resting blood pressure, heart rate, and weight measurements. NYHA classification was determined. Echocardiography and radionuclide ventriculography were performed to determine LVEF. Ischemic or valvular heart disease was defined according to previous history of confirmed MI, coronary artery bypass grafting, or coronary angiography with percutaneous coronary intervention and echocardiography. Patients were followed by a HF specialist at least once every 3 months.
The study endpoint was all-cause mortality.
Statistical analysis
Data are described using mean and standard deviation (SD) for continuous variables and frequencies for categorical variables. We considered 3 groups of patients based on quartiles of the distribution. The "lower" group included 25% of the patients with the lowest values of the variable, the "middle" group included 50% of the patients with the values of the variable between its first and third quartile, and the "upper" group included 25% of the patients with the highest values of the variable. Because of the small number of patients in NYHA class 1 and the unequal number of patients in NYHA classes 1 and 4, we defined 3 NYHA groups, namely NYHA 1-2, NYHA 2.5-3 and NYHA 3.5-4. In all regressions, we took the lower part as the reference to show the trend for hazard of death. This approach is widely used to study the effect of a continuous variable for the following reasons:
It avoids assumption of linearity; It provides a natural way to divide a population in the absence of officially accepted cut-off points; and Sometimes it is preferable to study a small or moderate sample, even when there are accepted cut-offs, to increase the power if some categories include a small proportion of the sample.
Specifically, the parameters were grouped as: monocytes (Group 1: 6%, Group 2: 6.1%-14%, and Group 3: >14%); LVEF (group 1: 40% and group 2: >40%). The Kaplan-Meier method was used to compute the product-limit estimate survival According to the goal of the study, we investigated prognostic values of the initial tests. This approach is standard in studies of specific subpopulations. Using initial values allowed us to build survival curves for the selected subgroups and to define the subpopulations at higher risk for poor outcomes.
We used expert controlled backward elimination in multiple Cox proportional hazard regressions where the least significant variable at each step was excluded if it agreed with expert opinion.
All calculations were done using STATA SE software. All tests were two-sided, and P values <0.05 were considered statistically significant.
There were clinical suspicions that the effect of monocytes might differ between patients with nonischemic cardiomyopathy (NICM) as compared to the other (non-NICM) patients. The cohort included 28 NICM patients. We calculated the effects of monocytes in both NICM and non-NICM groups. They were almost identical. In addition, we repeated the multiple regression with the non-NICM group and results were similar to those of the entire data set. Therefore, we present the results of the entire patient population.
Results
A total of 338 consecutive outpatients with congestive HF (ischemic or valvular origin) were included in this retrospective study. Thirty five were excluded due to technical reasons, noncompliance, or lack of follow-up information.
The remaining 303 patients had a mean ± SD age of 71.3 ± 11.2 years and they made up the study cohort. Mean follow-up was 11.3 years (range 1 month to 16 years) and 78% of the participants were admitted to the hospital during their course of follow-up. Clinical and laboratory findings at the first hospitalization of all the participants are presented in Table 1 . The mean NYHA classification was 2.8. Due to the small number of patients in NYHA class 1 and the unequal number of patients in NYHA classes 1 and 4, we divided the study sample into 3 categories (statistically), that is, NYHA 1-2, NYHA 2.5-3, and NYHA 3.5-4. The mean monocyte count (percent of total white blood cells) was 10.3 ± 5.5% and the mean LVEF was 36%.
The general characteristics of the patients and the mean distribution of selected clinical and laboratory parameters according to the 3 monocyte groups are shown in Table 2 . The monocyte groups differed in lymphocyte counts (P = .0006), high density lipoprotein (HDL) level (P = .033), and alkaline phosphatase level (P = .03). Patients in monocyte Group 3 (monocytes >14%) were somewhat younger than those in the other 2 monocyte groups, and slightly more were in a higher NYHA class (3.5-4) . Group 2 patients had lower NT-pro-BNP levels (P = .046) and higher HDL levels (P = .033). There were no differences between monocyte groups in the prevalence of diabetes mellitus, hypertension, or ischemic heart disease. Hemoglobin, glucose albumin, creatinine, creatinine clearance test and C-reactive protein levels were similar for all 3 groups. Higher HDL level was associated with longer survival. There were no differences in the use of most medications (including those which prolong survival, such as beta blockers, ACE inhibitors) between the monocyte groups, except for warfarin (P = .04), which was much less frequent among group 3 patients (Table 3 ). Figure 1 displays the Kaplan-Meier survival mortality curves according to the 3 monocyte groups. Group 3 (monocyte count >14%) had the best long-term survival (88% survived) and Group 1 (monocyte count 6%) had the poorest outcomes. This trend remained consistent for shorter periods, as well. Figure 2 illustrates the Kaplan-Meier mortality curves according to LVEF (40%) and monocyte count of Group 1 patients (28% and 18%, respectively) and was significantly less than that of the Group 3 patients (P < .001). Group 3 patients survived significantly longer (above 83%) independent of LVEF value (>40% or 40%). The highest survival was observed in the subgroup with monocytes >14% and EF >40%. Figure 3A , B, C show the survival rates of the 3 monocyte groups according to NYHA Class. Patients in the NYHA 1 + 2 group with a monocyte count <6.0% had a poorer survival rate (29%) than did the patients in Group 2 (80% survival) and those in Group 3 (>85%; P < .001) (Fig. 3A) . The same trend was observed in patients with NYHA Class 2.5-3 (Fig. 3B ). Survival in Group 1 was 22%, in Group 2, 69% and in Group 3 it was more than 82% (P < .001). For NYHA Class above 3, the survival rate for Group 1 was 12%, Group 2, 27% and in Group 3, 50% (P < .001; Fig. 3C ). Table 4 demonstrates the mortality hazard ratio (HR) of main clinical and laboratory parameters, adjusted for age and gender. It can be seen that, as related to the middle group, the lower group of monocytes had the highest hazard ratio (5.053) and the upper group had the lowest hazard ratio (0.042). Table 5 shows a concise proportional regression model of mortality and significant hazard ratios of the main clinical and laboratory parameters. Monocytes had the highest HR as did Nt-Pro-BNP that reached a level of significance. After periods of 1 year, 3 years, 5 years, and 10 to 12 years, the mortality was higher in Group 1: 69 of the 83 patients (83%) died during follow-up, as compared to 40 of 139 patients (29%) in Group 2, and 2 of 81 (2.5%) in Group 3.
Additional analyses were performed using absolute monocyte counts adjusted to hematocrit level. Since hematocrit does not change the proportion of monocytes, we adjusted only for absolute monocyte counts. We corrected for hematocrit in 2 ways. First, we defined a new variable equal to the absolute monocyte count divided by hematocrit and did the analysis using categories defined by this variable. Next, we included hematocrit in the Cox regression, in addition to absolute count and other covariates. As expected, there were strong correlations between the percent of monocytes and absolute monocyte count (0.819) Table 3 Frequency of medications according to monocyte groups (<6%, 6%-14%, >14%). and hematocrit-adjusted monocyte count (0.795). We found that the percent of monocytes had the strongest effect among all 3 definitions. In the Cox regression of survival on gender, age, and the 3 groups of monocytes, the effect of monocytes was similar.
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Discussion
Increased levels of eosinophils, [7, 8] monocytes, [9] [10] [11] neutrophils, [12, [18] [19] [20] [21] [22] [23] and decreased levels of lymphocytes [7] [8] [9] 12, [17] [18] [19] 21, [24] [25] [26] have been associated with increased risk of coronary heart disease and heart failure. [9, 18, 24] The results of the Japanese Adult Health Study showed a relationship between the total WBC count (including the eosinophil, neutrophil, and monocyte counts) and the incidence of coronary heart disease. [7, [12] [13] [14] In the current study, an increased monocyte count/percent had the best correlation with survival, as compared to other selected laboratory parameters. The following prognostic parameters were similar between survivors and non-survivors in all 3 groups: smoking, LVEF, diabetes, HTN, hyperlipidemia, hemoglobin level, CRP, renal function (which was moderately impaired in all groups, with a mean creatinine clearance of 42 ml/minute), albumin level, and oxidized LDL. However, lymphocyte count, Pro-BNP, and HDL levels differed among groups (P < .05). Several biomarkers are useful for prognosis prediction. These include NT Pro BNP, OX LDL, and CRP, which were measured in our study group. While CRP and OX LDL levels are useful when assessing the inflammatory process associated with atherosclerotic cardiovascular disease, NT Pro BNP is a biomarker that expresses poor hemodynamics associated with the failing heart. An emerging, new method that provides insight into the etiology of end-stage heart failure is based on the measurement of etiology-specific transcoronary concentration gradients of miRNA.
Our long-term results are in contrast to those reported in many studies that supported the theory that increasing monocyte count is associated with worse outcomes. [21, [12] [13] [14] [26] [27] [28] [29] [30] [31] [32] The results of these reports were explained by increased inflammatory activity (i.e., neurohumoral and oxidative stress with activation of inflammatory stress cells, such as neutrophils, eosinophils, and monocytes). [25, 26] Monocytosis was shown to be an independent marker of risk for coronary artery disease. This was based on significantly higher Mon1 and Mon2 in acute exacerbation of HF, as compared with stable chronic HF. In accord with this, patients with stable coronary artery disease had decreased amounts of classical monocytes (Mon1 and Mon2). In contrast "nonclassical" monocytes (Mon 3) were higher (and may be responsible for monocytosis) in stable coronary artery disease [29] and prevalent (90%) in healthy subjects with normal coronary arteries, as determined by angiography. [29] The findings of the current study indicated trends of an association of low total monocyte counts with increased mortality in well-controlled HF.
In agreement with our findings, Shimoni et al [27] reported that patients with severe aortic stenosis have lower monocyte counts than did patients with less prominent stenosis. The long-term prognostic value of low total monocyte count was examined in several studies that noted an association with increased risk for mortality in HF patients. [28] [29] [30] [31] [32] [33] [34] [35] [36] In other inflammatory and malignant diseases, such as follicular lymphoma, increased absolute monocyte count was associated with longer survival. [22] Monocytopenia was also reported in conditions with poor prognosis, such as ischemic stroke and Alzheimer's disease. [37] [38] [39] There was no association between low monocyte counts and other prognostic parameters, such as NYHA class, LVEF, Creactive protein level and others, and no other correlations were found, except for Pro-BNP level, lymphocyte count (%) and HDL. More Group 3 patients (monocyte count >14%) survived (above 83%), in both LVEF groups-(40 and >40). In contrast, the fewest survivors were observed among Group 1 patients (with monocyte count 6%, regardless of LVEF); 18% for 40 and 28% for >40. NYHA Class 1 + 2 group with a monocyte count <6.0 had poorer survival (29%) rate than the patients in Group 2 and Group 3 did. In NYHA class 2.5-3, the best survival was observed among Group 3 patients, at 82%. NYHA class >3, Group 3 patients with a monocyte count >14% showed 50% survival (P < .001). Our patients who survived longer than 15.9 years had a 50% higher monocyte count as compared to patients with shorter survival. The major finding of the current long-term, longitudinal study, in contrast to previous reports, [14, 15] is that a low monocyte count appears to be an important predictor for mortality in chronic, well-controlled, heart failure but not in exacerbations or acute heart failure.
One possible answer to the question of why different studies present conflicting results is that different subsets of monocytes (e.g., Mon3) are predominant in well-controlled, chronic HF. [7, 21, 29, [37] [38] [39] Monocytes play an important defensive role in several host functions, including initiating phagocytosis as a response to immune stimulation, removing cellular debris ("professional phagocytes"), secreting cytokines, and various substances that function as a self-defense mechanism and have antitumor effects, as well. [28, 29] Thus, stable coronary artery disease is associated with an increase in the non-classical, Mon3 monocyte subset, and increased expression of inflammatory markers on the monocytes. [29] Hence, we consider that stable, chronic HF is associated with increases in the non-classical monocyte subset. [21] The reported association between severe aortic stenosis with decreased total monocyte count [27] is in agreement with the current results. These findings may provide further clues to the mechanism underlying the pathogenesis of aortic stenosis. [27] To the best of our knowledge, this is the first report that describes a positive, predictive association of monocyte count and prognosis of stable, chronic HF.
A major limitation of this study is that monocyte subclasses were not analyzed prospectively. Using our set of inclusion criteria, we might have selected a subpopulation of participants who were at higher risk of mortality during the first 50 months from the beginning of the study. However, comparison of the subgroups that survived after this period showed significantly higher risk of mortality in the group with fewer monocytes despite the small number of events. This indicates that the effect of lower monocyte count was not limited to the initial period. [40] Additional, well-controlled, studies of heart failure patients and measuring Mon3 in subgroups will provide important clues as to whether monocyte counts can serve as a reliable, simple, easily available, and inexpensive prognostic parameter.
Conclusion
Patients with low monocyte counts were found to have lower rates of survival, as compared to those with higher counts, based on long-term follow-up. A high monocyte count was independently associated with better prognosis for these patients.
